We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Commenting on the news, Piper Jaffray analyst David Amsellem remarked that Rai's departure is good news for Akorn, noting that the drugmaker "could benefit from a new leadership team that is better versed in manufacturing operations and generics R&D."